B.P. Marsh sells Amiga stake to portfolio firm Sodalis for £1.8m

£1.8m: Sodalis Capital acquired 100% of Amiga Speciality Holdings for an initial consideration of £1.8m. B.P. Marsh will receive £706,250 cash for its 39.24% holding plus full repayment of a £1.825m outstanding loan, and may receive deferred consideration tied to Amiga performance in FY2027 and FY2028. Post-transaction B.P. Marsh retains a 25.55% equity stake in Sodalis (indirect exposure to Amiga) after its prior £5.3m November 2025 investment in Sodalis.

Analysis

Small, targeted buy‑and‑builds in specialty insurance create asymmetric optionality: a modest equity stake in an early roll‑up can act like a call option on consolidation economics (multiple expansion + operating leverage) without underwriting tail risk concentrated on the parent. The value hinge is earn‑out realization and the platform’s ability to internalize distribution economics — each additional bolt‑on that meaningfully raises retention rates or cross‑sell lifts margins much more than headline revenue growth, so track retention and cross‑sell KPIs closely over 12–36 months.

Second‑order winners include reinsurers and capacity providers who see sticky, higher‑margin specialty flows; they can reprice capacity favorably and extract better terms, which supports platform ROE even in a benign premium cycle. Conversely, large public brokers face margin pressure in niches where local roll‑ups deliver bespoke service — expect premium aggregation to compress some referral fees and accelerate selective verticalization of distribution.

Primary risks are idiosyncratic underwriting losses, misaligned earn‑out incentives, and liquidity/dilution if follow‑on funding is needed; a single mid‑sized loss year or higher cost of capital can wipe expected deferred consideration. Time horizons matter: near term (days–months) volatility is low, but the real value unlocks in 12–48 months when earn‑outs and strategic exits crystallize; monitor regulatory capital moves and reinsurance spreads as early warning indicators for reversal.

Contrarian angle: the market underweights the carry embedded in minority stakes inside active roll‑ups — if the operator can demonstrate 2–3 accretive bolt‑ons per year, a minority public holding can re‑rate by 30–60% without material premium tailwinds. That said, this view assumes competent capital allocation and low reinvestment capital needs; absence of either flips the thesis quickly, so governance signals (board composition, founder incentives) are a leading indicator of whether the optionality is real.

Key Decisions for Investors

• Initiate a small, tactical long in AIM:BPM (2–3% portfolio weight) with an 18–36 month horizon; target a 50–80% upside if earn‑outs are paid and the roll‑up executes 2+ accretive bolt‑ons, and use a 30–35% stop to limit illiquidity and idiosyncratic governance risk.
• Pair trade: long BEZ.L (Beazley) 1.5% vs short MMC (Marsh & McLennan) 0.75% (net market‑neutral bias) for 6–12 months — captures re‑rating of specialty underwriters vs large brokers if specialty distribution compresses referral margins; target net +30% vs max drawdown ~10% on the spread.
• Allocate a scouting capital line to pursue a private secondary or follow‑on in the roll‑up vehicle if offered (commit window 6–24 months); sizing should be opportunistic (max 1–2% NAV) aiming for >25% IRR on a 3–5 year hold, with liquidity and downside (total loss) priced into the bid.